电邮这篇文章 Interstitial pulmonary fibrosis: The role of angiogenic factors, the inhibitory pathways of progression
- 作者: Popova EN1, Lebedeva MV1, PonomarEv AB1, Popova IA1, Fomin VV1
-
隶属关系:
- ГБУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России
- 期: 卷 86, 编号 8 (2014)
- 页面: 23-28
- 栏目: Editorial
- URL: https://journal-vniispk.ru/0040-3660/article/view/31533
- ID: 31533
如何引用文章
全文:
详细
AIM. To assess the role of angiogenic factors (vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1) in interstitial lung diseases (ILD), such as fibrosing alveolitis, sarcoidosis. MATERIALS AND METHODS. The blood levels of endothelial dysfunction and neoangiogenesis markers (ET-1 and VEGF) were investigated in 96 patients with different clinical forms of ILD at it different stages; the found changes were compared with the clinical and morphological manifestations of the disease. RESULTS. It has been ascertained that regardless of the clinical type of ILD, there is a correlation between the blood levels of VEGF and ET-1 and the intensity of lung neoangiogenesis, the expression of VEGF by the endothelium of newly formed blood vessels, the production of angiogenic factors, the degree of endothelial dysfunction, the extent of pulmonary fibrosis, the degree of pulmonary vascular remodeling, and the severity of pulmonary hypertension. The findings suggest that the markers of neoangiogenesis play an important role in the mechanisms of ILD progression. CONCLUSION. The study of these parameters in the blood may be used to clarify the activity and prognosis of ILD.
作者简介
E Popova
ГБУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России
Email: ela12@yandex.ru
M Lebedeva
ГБУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России
A PonomarEv
ГБУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России
I Popova
ГБУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России
V Fomin
ГБУ ВПО "Первый МГМУ им. И.М. Сеченова" Минздрава России
参考
- Интерстициальные болезни легких: Практическое руководство. Коган Е.А., Корнев Б.М., Попова Е.Н., Фомин В.В. и др. Под ред. Н.А. Мухина. М: Литтерра 2007; 432.
- Abraham D. Role of endothelin in lung fibrosis. Eur Respir Rev 2008; 17: 109, 145-150.
- Katzenstein A.L., Mukhopadhyay S., Myers J.L. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol 2008; 39 (9): 1275-1294.
- Wells U., Hirani N. Interstitial lung disease guideline. Thorax 2008; 63 (Suppl. 5): 1-58.
- Чучалин А.Г. Идиопатический легочный фиброз. Тер арх 2000; 3: 5-12.
- Bikfalvi A. Angiogenesis: molecular mechanisms of activation, promotion and maintenance. J BUON 2007; 12 (Suppl 1): S59-S66.
- Borg G.A. Psycho-physical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377-381.
- Hamada N., Kuwano K., Yamada M. et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005; 175: 1224-1123.
- Попова Е.Н. Идиопатический фиброзирующий альвеолит и интерстициальные пневмонии. Клин мед 2005; 6: 21-27.
- Katzenstein A.L., Mukhopadhyay S., Myers J.L. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum. Pathol 2008; 39 (9): 1275-1294.
- Chan S.Y., Loscalzo J. Pathogenic Mechanisms of Pulmonary Arterial Hypertension J Mol Cell Cardiol 2008; 44 (1): 14-30.
- Farkas L., Farkas D., Ask K. et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009; 119 (5): 1298-1311.
- Chaudhary N.I., Roth G.J., Hilberg F. et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007; 29: 976-985.
- Kim R., Meyer K.C. Review: Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis 2008; 2: 319-338.
- Uguccioni M., Pulsatelli L., Grigolo B. et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995; 48: 330-334.
- Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocrine Rev 2004; 25 (4): 581-611.
- Montani D., Souza R., Binkert C. et al. Endothelin-1/Endothelin-3 Ratio. A Potential Prognostic Factor of Pulmonary Arterial Hypertension. Chest 2007; 131: 101-108.
- Voelkel N.F., Vandivier R.W., Tuber R.M. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006; 290: L209-L221.
- Walsh D.A. Pathophysiological mechanisms of angiogenesis. Adv Clin Chem 2007; 44: 187-221.
- Nakayama S., Mukae H., Ishii H. et al. Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Respir Med 2005; 99: 1145-1151.
- Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.
- Cottin V., Nunes H., Brillet P.Y. et al. Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26 (4): 586-593.
- Stenmark K.R., Fagan K.A., Frid M.G. Hypoxia-Induced Pulmonary Vascular Remodeling. Cellular and Molecular Mechanisms. Circ Res 2006; 99: 675-691.
- Takahashi M., Fukuoka J., Nitta N. et al. Imaging of pulmonary emphysema: a pictorial review. Int J Chron Obstruct Pulmon Dis 2008; 3 (2): 193-204.
补充文件
